SCHEMBL5351558

SCHEMBL5351558

COc1ccc(-c2nc(C)c(N)c(OC)n2)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRHR1 P34998 1/20 0.60
▸ ALDH1A1 P00352 5/20 0.46
▸ HTT P42858 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ NPC1 O15118 4/20 0.46
▸ ADORA3 P0DMS8 4/20 0.45
▸ CYP1A1 P04798 3/20 0.43
▸ CYP1B1 Q16678 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2E1 P05181 1/20 0.43
▸ CYP2C8 P10632 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2A6 P11509 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP4B1 P13584 1/20 0.43
▸ CYP2B6 P20813 1/20 0.43
▸ CYP3A5 P20815 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353273 0.82 CRHR1 (0.54) CRHR1ALDH1A1HTTGAAMAPK1
SCHEMBL5351554 0.80 CRHR1 (0.55) CRHR1ALDH1A1GAANPC1ADORA3
SCHEMBL6678654 0.79 CYP1A1 (0.58) CRHR1ALDH1A1HTTGAAMAPK1
SCHEMBL10486300 0.79 NPC1 (0.71) CRHR1ALDH1A1HTTGAAMAPK1
SCHEMBL5363181 0.76 CRHR1 (0.54) CRHR1ALDH1A1GAAADORA3KDM4E
SCHEMBL5363188 0.76 CRHR1 (0.61) CRHR1ADORA3CYP1A1CYP1B1CYP3A4
SCHEMBL7488832 0.76 CRHR1 (1.00) CRHR1
SCHEMBL7537463 0.73 CRHR1 (0.57) CRHR1ALDH1A1CYP3A4KDM4EMEN1
SCHEMBL15698789 0.73 ALDH1A1 (0.54) CRHR1ALDH1A1HTTGAAMAPK1
SCHEMBL8378539 0.72 NPC1 (0.66) CRHR1ALDH1A1HTTNPC1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7169790-B2 5-substituted 2-aryl-4-pyrimidinones NEUROGEN CORPORATION (US) 2007-01-30 — — US disclosed
US-20050234051-A1 5-Substituted 2-aryl-4 pyrimidinones NEUROGEN CORPORATION (US) 2005-10-20 — — US disclosed
US-6943173-B2 5-substituted 2-aryl-4-pyrimidinones NEUROGEN CORPORATION (US) 2005-09-13 — — US disclosed
EP-1301490-A2 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES NEUROGEN CORPORATION (US) 2003-04-16 — — EP disclosed
US-20020052387-A1 5-Substituted 2-aryl-4-pyrimidinones NEUROGEN CORPORATION 2002-05-02 — — US disclosed
WO-2002006242-A2 5-SUBSTITUTED 2-ARYL-4-PYRIMIDINONES NEUROGEN CORPORATION (US) 2002-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052387-A1 5-Substituted 2-aryl-4-pyrimidinones CRHR1, CRHR2, HTR4 CRHR1 1/4885ALDH1A1 1083/4885HTT 610/4885
US-20050234051-A1 5-Substituted 2-aryl-4 pyrimidinones CRHR1, CRHR2, HTR4 CRHR1 1/4885ALDH1A1 1148/4885HTT 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback